SiVEC Biotechnologies

SiVEC Biotechnologies aims to revolutionize the delivery of nucleic acids and other biologically active cargo to enable the development of safer and more effective therapies. SiVEC is a biopharma partnering company with a mission to provide a novel delivery platform that will support the translation of innovative nucleic acid and gene therapies from the R&D phase to the clinic and finally into the market. The company is focused on developing a drug delivery platform that is characterized as non-pathogenic bacteria that constitutively generate therapeutic nucleic acids for targeted intracellular delivery to mucosal epithelial cells. The bacterial delivery system is currently being used as a vehicle for delivery of an siRNA-based influenza antiviral in preclinical development.